Allopurinol, a drug used to treat gout, may slow progression of kidney disease in CKD patients, according to new findings scheduled to be published in an upcoming issue of the Clinical Journal of the American Society of Nephrology.
Marian Goicoechea, PhD, of Hospital General Universitario Gregorio Marañón, in Madrid, Spain, and colleagues conducted a prospective, randomized trial that included 113 CKD patients who received allopurinol (100 mg/day) or who continued taking their usual therapy (controls).
The allopurinol group, but not controls, experienced significant decreases in blood levels of uric acid and C-reactive protein (CRP), a marker of inflammation. After 24 months, the estimated glomerular filtration rate (eGFR) increased by 1.3 mL/min/1.73 m2 in the allopurinol group but decreased by 3.3 mL/min/1.73 m2 in the control group.
Allopurinol slowed renal disease progression regardless of patient age, gender, diabetes status, blood levels of uric acid and CRP, albuminuria, and use of renin-angiotensin system blockers. In addition, compared with standard therapy, allopurinol decreased the risk of cardiovascular events by 71% and the risk of hospitalizations by 62%.